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ABStrAct
Nyaope is a unique South African street drug mixture thought to contain illicit drugs 
and other compounds and is usually inhaled after wrapping in the Cannabis leaf. 
Despite its illegalization in March 2014, abuse of Nyaope is on the increase. While 
highly addictive, withdrawal symptoms are very severe, unbearable and drive the user 
to desperately seek for the next fix. Due to the lack of knowledge in its composition 
and how the constituents interact with each other, treatment for withdrawal symptoms 
and rehabilitation has been a challenge. A mini-literature review was done to explore 
how the major constituents of Nyaope relate to each other in their actions and in their 
path of breaking down (metabolism). The literature suggests that the inside opiate 
group, in between opiates and benzodiazepines, in between opiates and cannabis 
group, in between benzodiazepines and phenobarbitals, and also amongst the minor 
constituents, there are extensively shared the metabolic pathways which lead to 
longer plasma half-life in each of these drugs and thus synergistic effects. These shared 
pathways are via the cytochrome P450 family of enzymes in the liver cell cytoplasm 
and these enzyme actions are to inactivate or detoxify the drugs or convert them to 
more water soluble compounds in order to excrete them through the kidneys. Not only 
sharing the metabolic pathways, but also the actions of these drugs at certain receptors 
in the brain have either opposing or stimulating effects on one another, making the 
complex nature of their combined actions. Such findings can explain the unique 
withdrawal symptom complex of Nyaope, which is important for the clinicians and 
public health workers who are dealing with the users. Understanding the biochemical 
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introDuction
Nyaope is a mixture of street drugs 
commonly used in South Africa mostly 
consumed by the youth of poor socio-
economic background due to its avail-
ability and affordability in the town-
ships and informal settlement areas. In 
the recent years; the use of Nyaope has 
become a national crisis despite its ille-
galization in 2014. There have been as-
sumptions that it contains low grade her-
oin, marijuana, cleaning detergents, rat 
poison and chlorine, although these can-
not be confirmed due to lack of laborato-
ry infrastructure to analyse the mixture 
and difficulty in obtaining the mixture 
samples (Tau, 2013). Nyaope is cheap, 
costing only around Rand 30 (about 2 
USD) for one dose and easily accessible 
at the street corners and vendors in 
many townships. The Nyaope mixture is 
a brown coloured powder, thus can be 
easily disguised as soil or cement pow-
der. This poses difficulty in prosecuting 
the users especially because they can 
claim it as a pack of sand or soil since it 
is common practice in African culture to 
eat soil. The fact that the laboratories to 
verify if it is sand/soil or drug mixture are 
not readily available, the consumers or 
dealers always get away with processing 
the mixture.  Psycho-social factors such 
as unemployment, dropping out from 
school, lack of family and social support, 
homelessness and peer pressure are 
amongst other factors driving the abuse 
of this drug cocktail (Maseko, 2015).
In the past, laboratory analysis of 
Nyaope was not available due to diffi-
culties in obtaining specimens as well as 
the need to have a complex instrument 
and method to identify the individual 
component, thus the assumptions of 
what it may contain were based on the 
clinical presentation of the users after 
consumption and during withdrawal 
period. One study was done to analyse 
Nyaope samples in Gauteng province of 
South Africa recently to show the con-
stituents and their patterns across the 
samples (Khine, Mokwena, Huma & Fer-
nandes, 2015). 
Nyaope users present with a unique 
withdrawal feature of severe unbearable 
abdominal cramps, but other symptoms 
and signs are variable from one area to 
the other. There is no specific medical 
treatment for the users during withdraw-
al and rehabilitation. It would be benefi-
cial for the public health practitioners to 
understand what contributes towards the 
development withdrawal symptoms com-
plex so that they may improve the medi-
cal treatment. This literature review is to 
explore how the major constituents of 
Nyaope share their metabolic pathways 
leading to interactions and synergistic 
effects that may explain the withdrawal 
symptoms, which is important for the cli-
nicians and public health workers dealing 
with the users.
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and metabolic basis of Nyaope drug interactions provides valuable insight towards the 
development of withdrawal signs and symptoms which may contribute to the targeted 
treatment program. 
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MethoD
This is an unsolicited submission where 
the researcher believes there is a need to 
review the available literature to close the 
gap in knowledge and report the findings. 
The study is a status quo review of the giv-
en topic (drug mixtures and interactions) 
on the most current and focussed studies 
which are compared and summarised on 
the basis of the author’s experience and 
existing theories. Findings are qualitative 
nature and used to understand the nature 
of interactions between different drug 
classes found in the mixture. 
The bibliographic databases used were 
Cochrane library and Google scholar and 
inclusion criteria were 1) full text articles 
and studies 2) period from 2003 to 2016 
and 3) search words used were; drug 
mixtures, drugs of abuse, poly drug use, 
drug synergy, interactions, toxicity and 
metabolism. Search strategies were 1) 
using these words separately in the ini-
tial search, 2) then again by combining a 
few of these [e.g. poly drug use and me-
tabolism] [drug synergies and metabo-
lism], 3) lastly by specifying drug classes 
and combining phrases [e.g. opiates and 
opioids co-use and metabolism] [ opiates 
and benzodiazepines co-use and metabo-
lism] [ central nervous system stimulants 
and depressants co-use and metabolism] 
[illicit drugs and alcohol] [hepatic enzyme 
induction by phenobarbital and alcohol] 
[poly drug use and withdrawal effects] 
[poly drug use and toxicity].
There were a few limitations. Since 
Nyaope is unique to South Africa and 
due to its recent development, there are 
no studies done about it especially with 
respect to its compositions either in the 
country or in the world literature. Thus 
other mixtures alike (containing opiates 
and alcohol, opiates and benzodiazepines 
or Phenobarbitals were selected where 
available) and when literatures for the 
mixture format was not available, single 
drugs and their information were used. 
Moreover, two articles of 1996 were in-
cluded despite being out of determined 
period because the information they pro-
vide was essential and could not be found 
in more recent periodicals. 
In this review, also included was the im-
portant information from the interviews 
with the actual Nyaope users conducted 
by the co-author who is a public health 
practitioner as they may contribute in the 
understanding of withdrawal symptoms. 
LITERATURE REVIEW
Reports on the metabolism of each of 
the drugs found in the Nyaope mixture is 
presented together with how the drugs 
share the enzymes in their metabolic 
pathway which impact on their blood 
level and excretion. Reports on the clini-
cal effects of combining different class of 
drugs of abuse are also discussed. The 
findings are categorized in the following 
table and each is elaborated in the texts. 
Nyaope constituents
In 2014 the analysis of Nyaope samples 
was attempted using two Mass Spectro-
photometric methods to compare their 
performance in detecting the constitu-
ents. The time of flight mass spectrom-
etry was found to be a faster and more 
cost-effective method. In this study the 
Nyaope samples were obtained from vari-
ous townships and urban areas of North-
ern Gauteng and Mpumalanga provinces 
and analysis was done at the Perkin 






CNS depressants (Major constituents):
1)  Opiates (Heroin, Codeine, Morphine and Acetyl Morphine, meconin) Only one study found 
(Khine, Mokwena, Huma & 
Fernandes, 2015)
2)  Opioids (Methadone, Papaverine, Dimenoxitol, Benzitramide, thiofentanyl, 
tramadol)
3)  Non-opiate CNS depressants (Dextromethorphan, Benzodiazepines, 
Phenobarbitone)
CNS stimulants (Major constituents):
  Amphetamine, Meth-amphetamine (Kath/crystal meth), Cathine (beta hydroxyl 
amphetamine), Pipradrol (dopamine and Norepinephrine reuptake inhibitor), 
Fenelthylline (sympathomimetic bronchodilator).
Minor constituents:
  Acetaminophen, caffeine, antibiotics (citorflex), anti-retroviral (zidovudine), local 
anaesthetics (duracaine/lidocaine), plasticisers and calcium oxide ground material 
for binding and stabilisation of drugs.
2 Metabolism of Nyaope constituents
2.1 Opiates and opioids shared metabolism via 3 phases of hepatic cytochrome P450 
enzyme system in the liver and thus competition of enzymes amongst various drugs 




2.2 Cannabis and tetra hydro cannabis (THC) shared metabolism with opiates and 
opioids via P450 hydroxylation and oxidation systems.
(Sharma, 2012; Maurer, 
Saucer, & Theobald, 2006)
2.3 Benzodiazepines and opiates sharing metabolic paths via glucoronidation in the 
liver. When co-used with Phenobarbital, the latter produces tolerance of the former 
by inducing glucoronidation enzymes.
Oshiro (2013)
2.4 Phenobarbitals when co-used with opiates, alcohol or benzodiazepines, it stimulates 
the P450 enzymes for each of these co-used and metabolized them faster than usual 
leading to tolerance
Meyer (1996)
2.5 Amphetamine and methyl-amphetamine share demethylation pathway with opiates 
and opioids making their plasma levels higher 
Maurer, Kraemer, 
Springer, & Staack, 2004)
2.6 Minor constituents such as caffeine and acetaminophen (paracetamol) as well as 
Dextromethorphan, and Lignocaine also shared certain P450 enzymes called CYP3A4 
AND 1A2 with opiates and benzodiazepines. 
Meyer (1996)
3 Synergies amongst major drug groups in nyaope
3.1 Opiates, opioids and benzodiazepines sharing metabolism leads to higher intensity 
of euphoria and addiction.
Dean (2006)
3.2 Cannabis and THC up-regulate the opiate receptors in brain and  
potentiates opiate’s effect of CNS suppression, hence better pain relief  
and  stronger addiction.
(Cichewicz, 2004; 
Chimalakonda,  Seely, 
Bratton, Brents, Moran, 
Endres, & Moran, 2012)
3.3 Benzodiazepines and Phenobarbitals potentiate each other’s CNS depressant 
activities leading to severe drowsiness and disorientation 
National Institute on Drug 
Abuse,  2016
3.4 Amphetamine, Meth-amphetamine, Cathine-beta hydroxyl amphetamine, 
Pipradrol, and Fenelthylline synergize to give intense euphoria 
United States Maine County 
Law Department, 2010
3.5 cocaine, morphine and heroin, when added with meth-amphetamine, they together 
cause unbearable and severe abdominal cramps
Tiwari, Moghal, and 
Meleagrow (2006)
3.6 Paradoxical effects of CNS depressants and CNS stimulants Wise (1996)
3.7 Combination of anti-retro virals with drugs of abuse (Pal, Kwatra,  Minocha, 
Paturi, Budda, & Miltra, 
2011), Thomas and Velaphi 
(2014)
3.8 Combination of anti-histamines with opiates Sandor, 2000
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Johannesburg South Africa with the as-
sistance of a technical expert from the 
company. The details of the components 
consistently found in Nyaope are listed in 
the table 1. Rat poison and chlorine, pre-
viously thought to be in the mixture were 
not found in these samples. It was noted 
that the minor constituents were variable 
amongst the samples collected (Khine, 
Mokwena, Huma & Fernandes, 2015).
Metabolism of Nyaope constituents 
after consumption
Opiates, opioids and non-opiate CNS 
depressants 
The usual way of consumption is by 
wrapping the drug powder mix in the 
cannabis leave and smoking it inhaling 
through the mouth. The plasticiser in the 
mixture is thought to be enhancing the 
combustion. How drug residues get into 
the blood via the oral cavity or respira-
tory epithelium is now known. There is 
no study found regarding blood levels of 
drugs contained in the Nyaope mixture in 
the users after smoking. However, there 
are references to explain the fate of con-
stituent drugs in the user’s body. The opi-
ates and opioids are metabolised in the 
liver via two phases of reactions involving 
various groups of enzymes that belong to 
a family of cytochrome P450 in the liver 
cell cytoplasm. 
Phase I is the conversion of functional 
groups such as dehydrogenation/hydro-
genation, oxidation, hydrolysis (esterase), 
reduction and mono-oxygenation. The 
purpose of this phase is to reduce toxicity 
of each drug. Phase II is the process of de-
rivitisation of functional groups in order 
to produce water soluble metabolites to 
be excreted through the kidneys. These 
are glucuronidation, sulphation, acetyla-
tion, Glutathione (GSH-Conjugation) and 
Methylation. The metabolites produced 
from the two phases are less active than 
the parent drug or they may even be inac-
tive. However, some may have enhanced 
activity or toxic effects, including muta-
genesis, teratogenesis, and carcinogene-
sis, thus they need to be excreted through 
the kidneys efficiently.
In the context of opiates and opioids, 
only Morphine and its related compounds 
such as Hydromorphone and Oxo-mor-
phone) go through the phase II directly 
via the enzyme uridine diphosphate gluc-
uronyl transferrase 2B7 and its glucuro-
nide conjugates are excreted in the urine. 
The Codeine, Hydrocodone, Oxycodone, 
Methadone, on the other hand have to 
go through the phase I conversion using 
cytochrome P450 series of iso-enzymes 
(Smith, 2009) and from there on, directly 
excreted in the urine. The same applies 
to Tramadol (narcotic like pain killer) and 
Fentanyl (synthetic opiate and tranquil-
lizer). Certain CYP enzymes are shared 
amongst the opiates, Tramadol and Fen-
tanyl (CYP2D6, CYP3A4 are shared by 
more than one drug) (Smith, 2009).
The shared metabolic pathways lead 
to a longer half-life for each of the drugs 
with a synergistic effect leading to a lon-
ger lasting euphoria (along with analge-
sia). Moreover, the rate of conversion and 
conjugation into water soluble metabo-
lites would also be slower (as sharing the 
pathway), which lead to a reduced clear-
ance from the body (Meyer, 1996)
Cannabis and tetra-hydro cannabis (THC)
These are the major active compound 
of Marijuana leaves which are used to 
wrap the Nyaope mixture; are also me-
tabolised by the microsomal hydrox-
ylation and oxidation pathway of the 
CYP450 isoenzyme complex as shown 
DRUG MIXTURE “NYAOPE”
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in the figure 1. As Cannabis shares the 
metabolic pathway with most opiates and 
opioids via cytochrome enzymes CYP2D6 
and 3D4, this causes sluggish renal excre-
tion and increased blood levels of both 
groups which can result in a higher level 
of euphoria and a more severe addictive 
effect. The higher blood levels result in 
the tolerance to the effects of both drugs, 
making the user require another dose in 
a shorter time period (Maurer, Saucer, & 
Theobald, 2006).
Benzodiazepines 
These are also found in Nyaope and 
they get metabolized in the liver through 
the CYP450 iso-enzyme complex, many of 
which are shared by the opiates and canna-
binoids, and all metabolites of Benzodiaz-
epines go through the final glucuronidation 
pathway in the liver before excreted by the 
kidneys. Due to extensive sharing of CYP 
metabolic enzymes between Benzodiaz-
epines, opiates, opioids and cannabis, the 
CNS suppressant effects of each potenti-
ates that of the others; may lead to severe 
drowsiness in the users (Oshiro, 2013).
Phenobarbitals
This has also been found in some 
Nyaope mixtures and if the users consume 
alcohol at the same time as smoking 
Nyaope, both can stimulate most of the 
P450 enzymes and enhance the metabo-
lism of aforementioned drugs in Nyaope. 
This can lead to reduced plasma levels 
and increased tolerance, for example to 
Benzodiazepines (Meyer, 1996).
Amphetamine and methyl-amphetamine 
(CNS stimulants)
They constitute as major component of 
Nyaope and also get metabolized by the 
demethylation pathway of the CYP450 
(2D6, 1A2, 2B6, 3A4) iso-enzymes, thus 
sharing with most of the opiates (Maurer, 
Kraemer, Springer, & Staack, 2004). 
Other minor constituents
Amongst the minor constituents, caf-
feine and acetaminophen (paracetamol) 
as well as Dextromethorphan, and Lig-
nocaine (local anaesthetics) have been 
found in the Nyaope mixture and they are 
metabolized by the CYP3A4 AND 1A2 en-
zymes (Meyer, 1996). 
Drug Synergies between the major drug 
groups:
This means drugs with similar actions 
and when they are taken together, they 
potentiate each other’s action and re-
sultant effect is exponential. When opi-
ate and Opioids are combined, based on 
the shared metabolic pathways of opi-
ates mediated by cytochrome P450 liver 
enzymes, they inhibit the metabolism of 
each other, thus leading to longer plasma 
half-life and higher intensity of euphoria 
and addiction (Dean, 2006). Synergy be-
tween opiates and cannabis was found in 
animal studies where cannabis up-regu-
lates the opiate receptor proteins in the 
brain. This evidence provided the basis 
of better strategies in pain management 
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Figure 1. Metabolic route of Δ9-
tetrahydrocannabinol (Δ9_THC), its 
primary active metabolite 11-hydroxy-Δ9-
tetrahydrocannabinol (11-OH-THC) and 
the primary inactive metabolite, 11-nor-
9-carboxy-Δ 9-tetrahydrocannabinol 
(THCCOOH) (Sharma, 2012; Maurer, 
Saucer, & Theobald, 2006)
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of cancer patients (Cichewicz, 2004; Chi-
malakonda,  Seely, Bratton, Brents, Mo-
ran, Endres, & Moran, 2012). Combina-
tion of Benzodiazepines and Phenobar-
bitone was also synergistic as both are 
in the sedative group that suppress CNS 
and when taken together, this action is 
profound as they synergise each other. 
They cause severe drowsiness and lack 
of orientation in time, place and person. 
During withdrawal, restlessness, sleep 
disturbance, irritability, increased tension 
and anxiety, panic attacks, hand tremor, 
sweating, difficulty in concentration, dry 
wrenching and nausea, some weight loss, 
palpitations, and headache are common 
(National Institute on Drug Abuse,  2016).
The synergy also manifests in the ad-
verse effects of these combined drugs. 
For example, the gastro-intestinal symp-
toms are much more severe and some-
times unbearable when opiates such as 
cocaine, morphine and heroin are added 
with meth-amphetamine. There have 
been reports of life threatening abdomi-
nal complications that require surgery 
such as perforations due to mesenteric 
artery ischemia, reported by Tiwari, 
Moghal, and Meleagrow (2006) due to 
combination of opiates such as cocaine 
and heroin abuse. Severe chest pain due 
to ischemia of coronary vessels was also 
reported in another study by Burrows, 
Hagardorn, Harlan, Wallen, & Ferslew 
(2003) presented a case of a fatal drug 
interaction caused by ingestion of oxy-
codone and clonazepam. Oxycodone is 
an opium alkaloid used in long-term pain 
management therapy and Clonazepam is 
a benzodiazepine used for the treatment 
of seizures and panic disorders. The post-
mortem shows pathologies consistent 
with severe central nervous system (CNS) 
and respiratory depression produced by 
high concentrations of clonazepam and 
oxycodone including collapsed lungs, as-
pirated mucus, and heart failure. 
When looking at the combination of 
CNS stimulants and suppressants, al-
though it can be assumed that such 
combination would cancel each other’s 
effect, paradoxical effect of synergy was 
reported (Wise, 1996). Wise claimed 
that there is a summative effect of brain 
reward (natural satisfaction as in food, 
sexual activity or change in chemical bal-
ance) of median forebrain bundle fibres in 
the human brain when they are exposed 
to the mixture of opiates (codeine, mor-
phine, heroin) which are CNS suppres-
sants and the CNS stimulants such as 
amphetamines, caffeine, nicotine, can-
nabis and phencyclidine. The reason be-
hind this is because they share the site of 
stimulation in the brain through common 
mechanisms. The balance of these mixed 
effects is an enhanced stimulation in a 
shorter duration. This concept could be 
applicable in the case of Nyaope and also 
possible that since the amount of each 
drug is very small in the Nyaope mixture, 
the duration of stimulation is rather short 
but the height of euphoria causes stron-
ger addiction. 
In poly-drug use, the end result may lead 
to four possible outcomes such as null (can-
celling effect), overlapping and addition 
(synergistic effect) and antagonistic effects 
(United States Maine County Law Depart-
ment, 2010). For example, when central 
nervous system stimulants are combined 
(such as those found in Nyaope- Amphet-
amine, Meth-amphetamine, Cathine-beta 
hydroxyl amphetamine, Pipradrol, and 
Fenelthylline), they would lead to intense 
euphoria followed by severe side effects. 
Pupil size may be normal due to a cancella-
tion of the constriction effect of narcotics 
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(opiates) and dilatation effect of stimulants 
and Cannabis. A lack of the pupil conver-
gence effect however, can still be seen 
in the mixture of CNS suppressants and 
stimulant because the latter did not have 
any effect on it. A reaction to light would 
still be slow due to most of the drugs in the 
Nyaope mixture having this effect except 
Cannabis and anaesthetics. The pulse rate 
will depend on the proportion of Opiates, 
Opioids, Benzodiazepines, Phenobarbi-
tone versus Amphetamine and Cannabis in 
the mixture the user has taken. The same 
goes for the blood pressure. Body temper-
ature would be higher so long as there are 
CNS stimulant groups in the mixture, and 
the muscle tone (flaccid or rigid) would 
also depend on the proportion of suppres-
sants and stimulants, although Cannabis 
has no effect on muscle tone. The drowsi-
ness from Nyaope mainly comes from the 
combination of opiates, opioids and ben-
zodiazepines as additive effect. 
Combining Anti-retro viral therapy (ART) 
and drugs of abuse:
This was also seen in a few Nyaope mix-
ture and although the rationale behind 
the mixing is not clear, some users during 
the interview, mentioned that the drugs 
help with the headache and insomnia 
caused by the ART (Mokwena & Huma, 
2014).  In the report of Thomas and Vela-
phi (2014) a combination of anti-retro vi-
ral (ARV) compounds and drugs of abuse 
such as Morphine and Nicotine enhances 
the CYP3A4 and MDR1 (multi-drug resis-
tance protein) expression in vitro. Altered 
functions of efflux transporters within 
liver cells and CYPs in response to ARV 
and drugs of abuse may result in altered 
drug absorption and metabolism of both 
groups. Complexity underlying the rela-
tionship between efflux transporters and 
CYP makes it difficult to predict the out-
come of ARV therapy, particularly when 
HIV patients taking drugs of abuse do 
not adhere to this. HIV positive pregnant 
women on ARV medications and indulg-
ing in drugs of abuse, may develop a high-
er viral load due to such interactions, and 
lead to increase in mother to child trans-
mission of HIV (Pal, Kwatra,  Minocha, Pa-
turi, Budda, & Miltra, 2011). Thomas and 
Velaphi (2014) reported two cases of neo-
natal abstinence syndrome and low birth 
weight of babies born to mothers who 
are on ARVs and known to be addicted to 
Nyaope in South Africa. 
Combining antihistamines (cough syrup) 
in the nyaope mixture:
The Dexamethorphen can be purchased 
as over the counter cough medicine and 
when co-used with opiates; it enhances 
the binding of opiates and opioids to their 
brain receptors potentiating the eupho-
ria, but also contributes to the severity of 
combined drowsiness (Sandor, 2000)
DiScuSSion
It is not clear why the Nyaope mixture 
is formulated in this particular way. How-
ever, it can be postulated that it is based 
on the user’s experience of synergistic ef-
fects, but other constituents such as acet-
aminophen and caffeine could be to avoid 
the side effect of headache. The fact 
that some samples contain Methadone 
is quite alarming as it is not known how 
chronic use of this drug would influence 
the Methadone treatment for Heroin in 
the rehabilitation (Braude & Ginzburg, 
1986). Another author suggested that 
the rationale of combining CNS depres-
sants and stimulants seems to lie with the 
KHINE & MOKWENA
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purpose of cancelling out each group’s 
side effects as the former may lead to 
parasympathetic over activity and the lat-
ter, sympathetic counterpart (Armstrong 
& Cozza, 2003). Other minor components 
also seem to serve a specific purpose on 
their own, for example, plasticiser may 
enhance the stability of active ingredient 
powders in the mixture of ground cement 
or soil and it also accelerates the release 
of drugs from the matrix into the smoke 
upon burning. Plasticisers have been 
successfully used in the development of 
Transdermal drug administration such 
as skin patches for analgesics (Güngör & 
Erdal, 2011). The Local Anaesthetics (Du-
racaine/Lidocaine) is mildly euphoric and 
addictive (McLeod, 2015), but the ratio-
nale behind adding the antibiotics is not 
clear. In cases of Nyaope users who are al-
ready on ART, the rationale of mixing may 
be to curb the undesirable side effects of 
ARV such as headaches, insomnia or nau-
sea. However, in cases where user is not 
HIV positive, the reason of adding it is not 
known. Interviews with the users showed 
that they were not aware that the mix-
ture contained ARV. 
The constituents were found to be vari-
able from one area to another. This may be 
determined by the availability of raw ma-
terial and also the demand pattern from 
the regular users. Some of the constitu-
ents such as local anaesthetics and medi-
cation for induction in general anaesthesia 
are only available at the hospital pharma-
cy, and drugs such as antibiotics and an-
tiviral medication would need a prescrip-
tion, implying that some dealers may have 
connections to the these sources and that 
the operation of the Nyaope dealerships 
likely extends beyond the townships. 
From the observations of Nyaope users 
at the Rehabilitation centres by the public 
health practitioners (Mokwena & Huma 
2014) the main presentation features 
are severe chest pain, abdominal cramps 
(a feeling of explosions in the stomach), 
tremendous drowsiness, vomiting and 
sometimes diarrhoea. On a physical level, 
small pupils and high blood pressure with 
tachycardia is usually seen. Moreover, 
poor personal hygiene, signs of malnutri-
tion, dry skin and ulcers and marks due 
to old scars from obsessively scratching 
the skin (methyl amphetamine), thin and 
dehydrated face, burnt marks around the 
nostrils and mouth from combustion of 
certain drugs. There is also progressive 
weight loss from failure to eat and drink. 
Also reported are the feeling of irritability, 
insomnia, involuntary jaw clenching and 
tooth grinding. 
In terms of treatment options for the 
withdrawal symptoms, it is mainly sup-
portive and specific medication for sub-
stituting poly-drug use or the mixture is 
not available. A recommended treatment 
for chronic Heroin use is by substitut-
ing it with Methadone  (United States 
National Institute of Health (On Drug of 
Abuse) Annual report, 2012), but this re-
quires admission to a clinic for observa-
tion of treatment initially and followed 
by prescribing a maintenance dose of 
Methadone for a longer term (3-4 years) 
(Centre for Disease Control (CDC), 2002). 
The reason for observation is to ensure 
abstinence from Heroin and other drugs 
during therapy. The fact that the Nyaope 
mixture also contains Methadone de-
feats the purpose of Methadone based 
withdrawal treatment program as how a 
Methadone treatment would affect the 
other constituents in the Nyaope mixture 
has not been studied pharmacologically. 
Buprenorphine and Naltrexone are the 
other antidotes for opiates and they act 
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by antagonizing the opiate receptors, but 
due to the cannabis in Nyaope that in-
creases the opiate receptors in brain, and 
these antidotes would not be as effective 
as expected (Cichewicz, 2004).
concluSion
It is apparent from the literature re-
view that the major drugs of abuse con-
tained in Nyaope share the metabolic 
pathways leading to longer lasting plasma 
levels and synergistic effects of eupho-
ria, but the trade-off is the tolerance and 
aggravation of side effects constituting 
the unique withdrawal symptoms. Treat-
ment programs thus far are restricted 
to psycho-social therapy for behavioural 
change, and symptomatic treatment for 
withdrawal as specific medication for re-
habilitation of Nyaope is still a complex 
phenomenon due to the mixture of vari-
ous types of drugs. Understanding how 
metabolic pathways and drug interactions 
impact the clinical presentations in the 
users is thus important for the clinicians 
working in the withdrawal clinics and re-
habilitation centres.
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